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Abstract
Background: PMS2 expression loss was reported in a variety of human. However, its importance has not been
fully understood in cervical carcinoma. The aim of this study was to determine the expression of PMS2 in cervical
carcinoma and evaluate the significance of mismatch repair gene PMS2 regulated by glycogen synthase kinase 3b
(GSK-3b) in chemosensitivity.
Methods: We examined PMS2 and phosphorylated GSK-3b(s9) expression in cervical carcinoma tissues using
immunohistochemical staining. Furthermore, we detected PMS2 expression in HeLa cells and evaluate the
interaction with GSK-3b after transfection with GSK-3b by small interference RNA (siRNA), co-immunoprecipitation
and immunoblotting. We also evaluated the effect of PMS2 transfection on HeLa cells’ chemosensitivity to cisplatin
treatment.
Results: We found significant downregulation of PMS2 in cervical carcinoma, which was negatively associated with
phosphorylated GSK-3b (s9). Furthermore, we demonstrated GSK-3b transfection was able to interact with PMS2
and enhance PMS2 production in HeLa cells, and increased PMS2 production was responsible for enhanced
chemosensitivity.
Conclusions: Our results provide the evidence that stabilization of PMS2 production by GSK-3b was important to
improve chemosensitization, indicating the significance of GSK-3b-related PMS2 downregulation in the
development of cervical carcinoma and in developing a potential strategy for chemotherapy.
Background
Globally, cervical cancer is second only to breast cancer
as the leading cause of cancer death in women, with a
prevalence of 2.3 million cases and an annual incidence
of half million [1]. And approximately 275,000 women
die from this disease every year worldwide [2]. Despite
advances in the study of cervical cancer over the past 20
years, its pathogenesis is still not fully understood [3].
Mismatch repair (MMR) is one of the most important
DNA repair processes for maintaining genetic fidelity.
MMR deficiency leads to carcinogenesis through
increased mutation frequency, loss of cell cycle arrest,
and decreased apoptosis in response to DNA damage.
In addition to MSH2 and MLH1, other human mis-
match repair genes including MSH3, MSH6, MLH3,
PMS1, and PMS2 have been identified [4]. To date, a
disrupted MMR system has been identified in several
cancers, including hereditary nonpolyposis colorectal
cancer (HNPCC), and some sporadic cancers [5]. The
bulk of germline HNPCC mutations, roughly 90%,
resides in two MMR genes, MSH2 and MLH1, with
mutations in MSH6 (7-10%) associated with atypical
HNPCC [6]. However, PMS2 mutations are quite rare in
HNPCC as well as various other cancers [7-9].
It is very important to recognize that aberrant expres-
sion of MMR proteins has been reported to be asso-
ciated with increased risk of cervical cancer [10], low
and loss of expression of MMR in patients with cervical
cancer has been described by different groups as well.
For instance, Chung et al. showed loss of MSH2
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and Giarnieri et al. showed loss of MSH2 in 10 of 23
cervical cancers [12]. Ciavattini et al. recently found
MSH2 and MLH1 expression to be lower in 28 invasive
squamous cervical cancers compared to cervical intra-
epithelial lesions [13]. These findings therefore implied
that MMR may be also associated with the pathogenesis
of cervical cancer. The PMS2 gene encodes a MutL-
homologous protein that forms a heterodimer with
MLH1, and the resulting complex, MutLa, interacts
with MutSa/b to activate MMR. Because monomeric
PMS2 is highly unstable [14], and the reported mutation
rate of PMS2 is quite low in various cancers, we
hypothesized that certain types of exogenous DNA-
damaging agents may rapidly degrade PMS2 production
and disrupt the MMR system for facilitating carcinogen-
esis. Given that few data are available regarding PMS2
modulation in human cervical carcinoma, investigating
the mechanisms underlying the regulation of PMS2 may
be essential for understanding the significance of PMS2
in carcinogenesis.
To address this issue, we focused on the possibility of
modulation of MMR proteins by taking advantage of
Wnt signaling activation in this study, since certain key
components such as Glycogen synthase kinase 3b (GSK-
3b) in Wnt signaling have been implicated in a number
of cancers [15]. GSK-3b is active in resting cells, and it
is modulated by site-specific phosphorylation at the site
of s9 (inactivation) during cellular responses. We chose
GSK-3b and PSM2 in this study mainly because germ-
line PMS2 mutations are rarely reported, unlike other
components. On the other hand, our preliminary find-
ings demonstrated a consensus motif of VSSSH GPSDP
TDRAE in PMS2 (s499) by gene sequencing. This con-
sensus motif was shown to be the common phosphory-
lation motif recognized and activated by GSK-3b in
previous studies [16]. Our preliminary finding thus pro-
vides the possibility that the interaction of GSK-3b with
the PMS2 consensus motif contributes to maintaining
genomic stability and promoting protective responses of
mammalian cells to exogenous DNA damage (e.g., apop-
tosis). If so, the rapid induction and degradation of
PMS2 may be essential in the balance between cell sur-
vival and death as a sensor of environmental changes in
cervical carcinoma.
To verify this hypothesis, we examined the expression
of PSM2 protein in cervical cancer in this study, evalu-
ated the effects of cisplatin on PMS2 expression in
HeLa cells, and examined the importance of GSK-3b
binding on PMS2 stability and chemosensitization to
cisplatin in HeLa cells by taking advantage of co-immu-
noprecipitation (IP), small interference RNA (siRNA)
and flow cytometric analysis. Our finding therefore will
be helpful in clarifying the molecular mechanisms
involving the modulation of MMR proteins by Wnt sig-
naling in the development of cervical carcinoma and in
developing a possible therapeutic target for future
chemotherapy.
Methods
Materials
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), cisplatin (cis-diammine-dichloroplati-
num), dimethyl sulfoxide (DMSO), and lithium chloride
(LiCl), a GSK-3b inhibitor, were purchased from Sigma.
Human pGSK-3b (s9) and b-actin antibody were
obtained from Santa Cruz Biotech. MLH1, MSH2, and
PSM2 antibody was obtained from BD Biosciences. The
plasmids pCGN-GSK-3b (WT), pGEX-GSK-3b,c o n s t i -
tutively active GSK-3b (GSK-3b-CA; S9A GSK-3b),
kinase-dead GSK-3b (GSK-3b-KD; pCGN-GSK-3b-KD)
plasmids and pCGN-PMS2 plasmids were kindly pro-
vided by Dr. Qingqing Ding (MD Anderson Cancer
Center, Houston, USA). Plasmid vector GSK-3b siRNA
(pKD-GSK-3b-V1;Si-GSk-3b) was purchased from
Upstate Biotechnology. Enhanced chemiluminescence
western blotting detection reagents were purchased
from Cell Signaling. Transfection reagents (Lipofect-
amine 2000 and PLUS reagent) were purchased from
Invitrogen Corporation.
Immunohistochemical staining
For immunohistochemical staining, seventy-eight surgi-
cally resected human cervical carcinoma tissues were
collected from the Departments of Obstetrics and Gyne-
cology, Wuhan Union Hospital, and the study was
approved by the institutional review board. Immunohisto-
chemistry was performed according to our previously
described protocol [17]. Briefly, human tumor tissues
embedded in paraffin were cut into 5-μms e c t i o n sa n d
placed onto glass slides. After antigen retrieval, sections
were stained for the expression of MLH1 (1:50), MSH2
(1:50), PMS2 (1:100), and pGSK-3b (1:100), and then
detected by streptavidin-biotin-horseradish peroxidase
complex formation. Tumor sections stained by isotype
matched IgG instead of primary antibodies were used as
a negative control. The immunostaining was considered
positive when the tumour mass occupied more than 10%
of the cross-sectional core area and when 10% or more of
the neoplastic cells were stained.
Cell culture
Human cervical carcinoma HeLa cell lines (American
Type Culture Collection) were cultured in RPMI 1640
supplemented with 10% fetal calf serum (FCS) (Invitro-
gen), penicillin (100 units/mL), and streptomycin
(100 μg/mL; Invitrogen). All cultures were maintained at
37°C in a humidified atmosphere with 5% CO2.
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treatment
For plasmid transfection, HeLa cells were seeded in a
24-well plate at low densities overnight in RPMI 1640
supplemented with 10% FCS. Cells were transiently
transfected at 70% to 90% confluency, using the plasmid
DNA (up to 4 μg) mixed with the Lipofectamine 2000
reagent (Invitrogen) at the DNA (μg)/lipid (μL) ratio of
1:2.5. Silencing of GSK-3b was similarly performed with
Si-GSk-3b plasmids in HeLa cells. At 4-6 h post-trans-
fection, the plasmid- or siRNA-containing medium was
replaced with normal culture medium containing 10%
FCS, and the cells were incubated in a 5% CO2 incuba-
tor at 37°C. Transfected cells were then cultured in
fresh medium for up to 12 to 48 h and harvested for
gene expression and other assays. For specific blockage
of GSK-3b activity, LiCl (20 mM) was added to HeLa
cells simultaneously. For cisplatin treatment, various
concentrations (0-10 μg/ml) of cisplatin were added to
HeLa cells. DMSO alone and medium alone served as
controls. Time point chosen for cisplatin addition to the
transfected cells was 24 h after transfection, based on
preliminary experiments.
Assessment of cell viability by MTT Assay
Treated or untreated cells were seeded into 96-well
plates at 1 × 10
3 cells per well overnight and then incu-
bated with different concentrations of cisplatin (from 0
to 10 μg/ml). After culture for 24 h, 20 μlo fM T Td y e
solution (5 mg/ml) was added to each well, and samples
were incubated at 37°C for 4 h. The formazan product
was dissolved by adding 200 μLo fD M S Ot oe a c hw e l l ,
and the plates were read at 570 nm. Cell growth activity
was determined according to the formula for relative
cell viability (OD570 from treated cells/OD570 from
untreated cells ×100%). All measurements were done in
triplicate, and the results were calculated from three
independent experiments.
To determine the cytotoxicity of cisplatin and combi-
nation treatments of cisplatin and GSK-3b WT plasmid,
HeLa cells were seeded onto 96-well plates at a density
o f1×1 0
3 cells/well. Twenty-four hours later, the cells
were transfected with GSK-3b WT plasmid at different
concentrations (0, 1, 2, and 4 μg/ml). Cells treated with
PBS were used as a control. Cisplatin at various concen-
trations (0-10 μg/ml) was also added to each well. The
cells were incubated for 24 h, and cell growth and viabi-
lity were analyzed by the MTT assay.
The effects of the combination treatment of PMS2
plasmid and cisplatin were analyzed with CalcuSyn soft-
ware (Biosoft, Cambridge, UK) to determine the combi-
nation index (CI). Generally,i ti sc o n s i d e r e dt h a taC I
<1.0 indicates synergism, CI = 1.0 indicates an additive
effect, and CI >1.0 indicates antagonism.
Semi-quantitative RT-PCR analysis for PSM2 mRNA levels
Total RNA was isolated from HeLa cells after treatment
with cisplatin (10 μg/ml), using TRIzol reagent (Invitro-
gen) according to the manufacturer’s instructions. Total
RNA (2 μg) was reverse transcribed using M-MuLV
Reverse Transcriptase (Promega) and oligo(dT)18 as
primer. cDNA was amplified by PCR using Taq DNA
polymerase (Promega). The following primers were
designed for RT-PCR: PSM2 forward 5’-GAG AAC
CTG CTA AGG CCA TC-3’,P S M 2r e v e r s e5 ’-ATG
GTG ACA TCG CTC AGT GC-3’ (product size,
340 bp); b-actin forward 5’-ATC TGG CAC CAC ACC
TTC CA-3’ and reverse 5’-CTC CTT AAT GTC ACG
CAC GA-3’(product size, 476 bp). All the primers were
synthesized by Invitrogen. The thermocycling conditions
were as follows: 30 s at 94°C, 45 s at 56°C, 30 s at 72°C,
and 30 cycles followed by extension for 7 min at 72°C.
PCR products were analyzed with 1.5% agarose gel elec-
trophoresis in the presence of ethidium bromide for UV
light transilluminator visualization. The relative PSM2
mRNA level was normalized to b-actin with Bio-Rad
Quantity One 1-D Analysis Software (Bio-Rad). The
experiment was repeated in triplicate.
Immunoprecipitation and Immunoblotting analysis
Treated and untreated HeLa cells were lysed for 10 min
on ice with the same lysis buffer used for immunoblot-
ting. Following centrifugation at 14,000 g for 10 min at
4°C, 1 ml of clear lysates was incubated with 5 μl of rab-
bit anti-GSK-3b antibody or 5 μlo fn o r m a lg o a tI g G
overnight with continuous rotation at 4°C. Protein
A-sepharose beads (30 μl) were then added, and the
samples were gently rocked 4°C for 3 h. After five
washes with lysis buffer, the beads were recovered and
resuspended in 40 μl of 2× SDS sample buffer (4% SDS,
0.125 mol/l Tris-HCl, 20% glycerol, and 0.04% brom-
phenol blue, pH 6.8) and then boiled for 5 min. The
co-immunoprecipitation (IP) proteins dissociated from
the beads were used for immunoblotting analysis.
Immunoblotting was done as previously described
[18]. Briefly, Treated and untreated HeLa cells were
washed in cold PBS three times, and total cellular pro-
tein was extracted in 100 μl of RIPA lysis buffer (Pierce)
at 4°C for 30 min. The protein concentration was deter-
mined by the Bradford method (Pierce). Samples con-
taining 10 μg of protein were boiled and subjected to
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) on 10% Tris-glycine gels and trans-
ferred electrophoretically to a polyvinylidene fluoride
membrane. Primary antibodies (mouse anti-human
PSM2, rabbit anti-human GSK-3b,a n db-actin mono-
clonal antibody, 1:2,000) were used, followed by horse-
radish peroxidase-linked secondary antibody (goat
anti-mouse IgG, 1:1,000) and visualized by Enhanced
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d e n s i t yo fP S M 2o rG S K 3 b to b-actin was quantified
with Bio-Rad Quantity One 1-D Analysis Software (Bio-
Rad). The experiment was repeated in triplicate.
Immunofluorescence staining
Treated and untreated HeLa cells in an eight-well Lab-
T e kI IC h a m b e rS l i d eS y s t e m( N a l g eN u n cI n t . ;7 0 %
confluence) were fixed with 4% paraformaldehyde in
P B Sf o l l o w e db yi n c u b a t i o ni n0 . 5 %T r i t o nX - 1 0 0i n
PBS. After several washes, cells were blocked with 3%
bovine serum albumin in PBS followed by incubation
with mouse anti-PSM-2 (1:100) and rabbit anti-GSK-3b
( 1 : 1 0 0 )a n t i b o d i e sa t4 ° Co v e r n i g h ti nah u m i d i f i e d
chamber. The cells were subsequently exposed to Texas
red or FITC-labeled secondary antibodies (Santa Cruz
Biotech) (1:200). The labeled cells were detected under a
fluorescence microscope. Cells incubated with fluores-
cein-conjugated secondary antibodies in the absence of
primary antibodies served as negative controls.
Apoptosis assay by flow cytometric analysis
Treated and untreated HeLa cells were stained with
annexin-V and PI using a Vybrant Apoptosis Assay Kit
(Invitrogen) according to the manufacturer’si n s t r u c -
tions. Briefly, HeLa cells were seeded onto 24-well plates
for 24 h. The cells were then transfected with PMS2
plasmid (2 μg/ml). Various concentrations of cisplatin (0
or 10 μg/ml) were also added to each well. Cells treated
with empty plasmid were used as a control. The cells
were incubated for 24 h and were used for analyzing
apoptosis and caspase-3 activity. For the apoptotic assay,
HeLa cells were harvested and washed once with cold
PBS. Cell pellets were re-suspended in 100 μL1 ×
annexin-binding buffer and 5 μL of FITC-annexin-V
(component A), and 1 μL of the 100 μg/mL PI working
solution was added to each 100 μL of cell suspension.
The cells were incubated on ice for 1 h, washed with
cold PBS once again, and re-suspended in 300 μLo f1 ×
annexin-binding buffer, and the stained cells were ana-
lyzed for apoptosis by flow cytometry soon after
staining.
Determination of caspase-3 activity
The activity of caspase-3 was measured using the cas-
pase-3 activation kit (R&D systems, Inc., Minneapolis,
MN), according to the manufacturer’s protocol. Similar
to the apoptotic assay, HeLa cells were transfected with
PMS2 plasmid (2 μg/ml), and cisplatin of various con-
centrations (0-10 μg/ml) was also added. The cells were
incubated for 0-36 h, and total protein in HeLa cells
was extracted with RIPA lysis buffer and quantified by
the Bradford method. One hundred micrograms of total
protein was added to each well in 96-well microtiter
plates (Bio-rad) with DEVD-pNA at 37°C for 1-2 h. The
optical density of each well was measured at 405 nm
using a microplate reader. Each plate contained multiple
wells of a given experimental condition and multiple
control wells. The activity of caspase-3 was expressed in
arbitrary absorbance units (absorbance at a wavelength
of 405 nm).
Statistical analysis
The Chi-square test was employed to analyze the posi-
tive rate of immunohistochemistric staining, and the
correlation between pGSK-3b (s9) expression and MMR
gene levels. Differences between different groups of
HeLa cells in protein analysis, cell viability assays, and
apoptosis studies were analyzed using ANOVA and
a two-tailed t-test. The significance level was set at
P < 0.05.
Results
Expression of PMS2 and pGSK-3b in human cervical
carcinoma tissues
Few studies have described the clinical features of cases
with PMS2 production in cervical carcinoma tissues up
to now, but aberrant expression of MSH2 was shown to
increase the risk in early stages of cervical carcinoma. To
investigate the importance of the MMR genes (MSH2,
PMS2) in cervical carcinoma and possible regulation by
GSK-3b, we examined expression of MLH1, MSH2,
PMS2, and pGSK-3b(s9) by immunohistochemistric stain-
ing. The clinical pathologic characteristics of specimens,
including tumor size, lymph node status, tumor grade,
distant metastasis and biomarker expression were
obtained and are listed in Table 1. Of 78 tumor sections,
54 (69.2%) showed positive immunostaining for MLH1,
Table 1 Description of the patient population and
biomarker expression
Characteristic Patients (n = 78)
Age (Median ± SD) 47.2 ± 26.7
Histology
Undifferentiated 51 (65.3%)
Differentiated 27 (34.7%)
Primary tumor stages
T(1) 29 (37.2%)
T(2) 11 (14.1%)
T(3) 25 (32.1%)
T(4) 13 (16.6%)
Nodular metastasis
Yes 22 (28.2%)
No 56 (71.8%)
Distant metastasis
Yes 7 (8.9%)
No 71 (91.1%)
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26 (33.3%) were positive for PMS2, and 48 (61.5%) were
positive for pGSK-3b (s9). Representative examples of
immunostaining slides are shown in Figure 1.
Because phosphorylation of s9 is known to inactivate
GSK-3b kinase activity and can be used as a measure-
ment of inactivation, we compared expression of MLH1,
MSH2, and PMS2 with pGSK-3b(s9) level in cervical
carcinoma. We found a statistically significant negative
correlation between pGSK-3b(inactivation of GSK-3b)
and PMS2 in cervical carcinoma (Table 2) (P =0 . 0 0 1 ) ,
while pGSK-3b did not show a statistically significant
correlation with MLH1 and MSH2 immunoreactivity
(data not shown). Our results suggested that the
downregulation of PMS2 in cervical carcinoma tissues
might be associated with pGSK-3b production and
GSK-3b inactivation. Our results therefore have pro-
vided the possibility that GSK-3b is able to stabilize
PMS2 production in human tissues.
Figure 1 Immunohistochemical staining of pGSK-3b, PMS2, MLH1, and MSH2 in human cervical carcinoma tissues. Representative results
of immunostainings were presented. (A) PMS2 positive stain in human cervical carcinoma tissues (× 400); (B) pGSK-3b negative stain in human
cervical carcinoma tissues (× 400); (C) PMS2 negative stain in human cervical carcinoma tissues (× 400); (D) pGSK-3b positive stain in human
cervical carcinoma tissues (× 400); (E) MLH1 positive stain in human cervical carcinoma tissues (× 200); (F), MSH2 positive stain in human cervical
carcinoma tissues (× 400).
Table 2 Correlation between pGSK-3b (s9) expression and
PMS2 expression in cervical carcinoma patients
pGSK-3b (+) pGSK-3b (-)
No (%) No (%) x
2 value P value
PMS2
(-) 38 14 8.775 P = 0.001
(+) 10 16
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increases PMS2 production
It is well known that chemosensitization to chemothera-
peutic agents usually is thought to result from apoptosis
induction and functional MMR and drug resistance is
associated with MMR deficiency, we thus postulated that
treatment with cisplatin on HeLa cells may result in an
MMR response and PMS2 upregulation. To determine the
optimal concentration of cisplatin for evaluating PMS2
expression in the following step, we first investigated the
effect of cisplatin on the growth of HeLa cells by MTT
assay after treatment with cisplatin for 24 h. As illustrated
in Figure 2, we found that treatment with different con-
centrations of cisplatin (from 0 to 10 μg/ml) for 24 h sig-
nificantly decreased the cell growth of HeLa cells when
compared to the control (P < 0.05), showing a concentra-
tion-dependent suppression. We therefore determined the
optimal concentration of cisplatin as 10 μg/ml for further
study on the basis of the growth curve of HeLa cells. We
then examined the level of PMS2 protein in HeLa cells
using western blotting after treatment with cisplatin
(10 μg/ml) for 24 h. As illustrated in Figure 3, we observed
Figure 2 Cell viability after cisplatin administration for 24 h in HeLa cells. Treatment with different concentrations of cisplatin (from 0 to 10
μg/ml) for 24 h significantly decreased the cell growth of HeLa cells compared to the control, showing a concentration-dependent suppression.
(A) Cell growth curve after different concentrations of cisplatin administration for 24 h; (B) Suppression of cell growth after different
concentrations of cisplatin administration for 24 h. * P < 0.05, ** P < 0.01, compared to the control cells.
Figure 3 Levels of PMS2 mRNA and protein in HeLa cells after cisplatin administration. (A), PMS2 mRNA expression was significantly
upregulated after treatment with cisplatin (10 μg/ml) for 24 h, as determined by semi-quantitative RT-PCR; (B), PMS2 protein level was
significantly upregulated after treatment with cisplatin (10 μg/ml) for 24 h, as determined by immunoblotting. * P < 0.05, compared to the
control cells.
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cisplatin treatment was shown to significantly increase the
PMS2 production in HeLa cells, which was consistent
with the mRNA expression. These results suggested that
PSM2 was upregulated significantly at both the mRNA
and protein level, and that it may contribute to the cispla-
tin-induced apoptosis in HeLa cells.
Evidence indicates the interaction of GSK-3b and
PMS2 in HeLa cells
Given that preliminary sequence analysis of PMS2
indicated that there exists a consensus motif of phosphory-
lation in the PSM2 gene which can be recognized and acti-
vated by GSK-3b, we hypothesized that GSK-3b is able to
stabilize PSM2 by binding to the specific phosphorylation
motif. To investigate the effect of GSK-3b on PMS2 pro-
duction in HeLa cells, we transfected GSK-3b WT plasmid
into HeLa cells and harvested the cells after 24 h for Co-IP
and immunoblotting analysis. We evaluated the association
between GSK-3b and PMS2 by using IP with an antibody
to GSK-3b and immunoblotting with an antibody to
PSM2. As illustrated in Figure 4A, we detected PSM2 pro-
duction in the IP complex, indicating an interaction
between GSK-3b and PMS2 in HeLa cells.
To further determine the effect of GSK-3b activity on
PSM2 production in HeLa cells, we divided HeLa cells into
three groups and transfected them with GSK-3b WT,
GSK-3b CA, or GSK-3b KD plasmids and harvested the
cells 24 h after for immunoblotting analysis. We then com-
pared PMS2 production in the different transfection
groups by immunoblotting analysis. As illustrated in Figure
4B, our results show that PMS2 production in the GSK-3b
WT and GSK-3b CA groups was significantly higher than
that in the GSK-3b KD group and control, indicating that
GSK-3b WT and GSK-3b CA plasmids were able to stabi-
lize PMS2 production in HeLa cells (P <0 . 0 5 ) .
We then used LiCl, a specific inhibitor of GSK-3b, and
GSK-3b siRNA to further evaluate the effect of blocking
Figure 4 Evidence indicates the interaction of GSK-3b and PMS2 in HeLa cells. (A) Representative result of IP and immunobloting was
presented after GSK-3b WT plasmid transfection. Interaction of GSK-3b and PMS2 in HeLa cells was suggested by using IP with an antibody to
GSK-3b and immunoblotting with an antibody to PSM2; (B) Representative result of immunobloting was presented after GSK-3b plasmid
transfection and Lithium administration; (C) GSK-3b significantly enhanced PMS2 production in HeLa cells, which was reversed by 20 nm of
Lithium administration, * P < 0.05, compared to the control cells; ** P < 0.05, compared to the transfected cells; (D) Representative result of
immunobloting was presented after GSK-3b plasmid transfection and RNA interference; (E) GSK-3b siRNA significantly reversed GSK-3b-enhanced
PMS2 production in HeLa cells in a concentration-dependent fashion, * P < 0.05, compared to the control cells; (F) PMS2 protein was
downregulated significantly after GSK-3b siRNA administration, showing a dose-dependent correlation (r = 0.792, P < 0.05).
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HeLa cells. As illustrated in Figure 5C, we found that
blocking GSK-3b activity with Lithium (20 mM)
resulted in significantly downregulated PMS2 produc-
tion in the GSK-3b WT and GSK-3b CA groups (P <
0.05), while there was no significant alteration of PMS2
production in the GSK-3b KD group after LiCl adminis-
tration. We used GSK-3b WT-transfected HeLa cells as
a control and found that PMS2 production was shown
to be upregulated significantly in HeLa cells compared
to non-transfected cells. Consistent results were
observed in HeLa cells transfected with different con-
centrations of GSK-3b siRNA (1-4 μg) (Figure 4D, E).
After GSK-3b siRNA administration, we observed that
PMS2 protein levels were downregulated significantly
compared to the control (P <0 . 0 5 ) ,s h o w i n gad o s e -
dependent correlation. We also examined the co-loca-
tion of GSK-3b and PMS2 protein in HeLa cells by
indirect immunofluorescence staining. As shown in
Figure. 5, we found the immunostaining of GSK-3b was
cytoplasmic and partly nuclear in HeLa cells, and PMS2
presented a similar distribution. Furthermore, transfec-
tion with GSK-3b WT and GSK-3b CA plasmids
increased the intensity of both GSK-3b and PMS2
expression, compared to the control. Conversely, GSK-
3b KD did not increase the intensity of either GSK-3b
or PMS2 expression in HeLa cells. Together, these
results provide evidence that GSK-3b is able to stabilize
PMS2 production in HeLa cells.
PMS2 transfection enhances chemosensitization
of HeLa cells to cisplatin
To further characterize the importance of PMS2 in
improving chemosensitization of cervical carcinoma, we
analyzed the effects of PMS2 transfection on apoptosis
of HeLa cells induced by cisplatin using flow cytometry.
A ss h o w ni nF i g u r e .6 A ,P M S 2p r o d u c t i o nw a sd e m o n -
strated to be elevated in HeLa cells after transfection for
0-36 h at a dose of 2 μg/ml.
For apoptotic analysis, HeLa cells were treated with
PMS2 plasmid at a dose of 2 μg/ml or cisplatin at a
concentration of 10 μg/ml, or a combination of the two.
Figure 5 Co-location of GSK-3b and PMS2 production in HeLa cells after GSK-3b transfection, as indicated by indirect
immunofluorescence staining. Representative results for GSK-3b and PMS2 immunostaining were presented (200×). Immunostaining of GSK-3b
was cytoplasmic and partly nuclear in HeLa cells, while PMS2 was mainly located in the nucleus. Transfection of GSK-3b WT and GSK-3b CA but
not GSK-3b KD increased the intensity of PMS2 expression in HeLa cells, compared to the control. GSK-3b was labeled with Texas Red-
conjugated secondary antibody, while PMS2 was labeled with FITC-conjugated secondary antibody. The right lane indicated co-location of GSK-
3b and PMS2 in the merged image in HeLa cells.
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cence-activated cell sorting (FACS) analysis of Annexin
V and PI stained cells at 24 h after the drug treatment.
When compared with cells treated with PBS, PMS2, or
cisplatin alone, we observed that the combination of
PMS2 and cisplatin showed a significant increase of
apoptosis in HeLa cells. As illustrated in Figure 6B, we
found that the number of early apoptotic cells (Annexin
V
+/PI
- cells) and the number of total apoptotic cells
(Annexin V
+ cells) were increased 2.4-fold and 2.1-fold
(P < 0.05), respectively, when compared to the untreated
cells. This indicated that transfection of PMS2 plasmid
Figure 6 PMS2 enhanced cisplatin-induced apoptosis in HeLa cells indicated by flow cytometric analysis. HeLa cells were transfected
with PMS2 plasmid (2 μg/mL) and followed by treatment with cisplatin for 0-36 h. (A) PMS2 production was demonstrated to be elevated in
HeLa cells after transfection for 0-36 h at a dose of 2 μg/ml. Representative results of western blot were shown. (B) PMS2 transfection (24 h)
significantly enhanced cisplatin-induced apoptosis in HeLa cells. Annexin
+/PI
+ cells indicate late apoptosis cells and Annexin
+/PI
- cells indicate
early apoptosis cells. Representative results of apoptosis assay using the AnnexinV-FITC Apoptosis Detection Kit as described in Method Section
was shown. The results are representative of two independent experiments. * P < 0.05 compared to the control cells.
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Page 9 of 13significantly enhanced cisplatin-induced apoptosis of
HeLa cells, showing an enhanced chemotherapeutic
effect. Consistently, caspase-3 activity was shown to be
significantly increased after administration of the PMS2
plasmid in cisplatin-treated HeLa cells for 0-36 h (P <
0.05) (Figure 7A).
The effect of combined PMS2 transfection and cispla-
tin therapy on the HeLa cells was also evaluated in our
cell system. The cells were first transfected with PMS2
plasmid (0-4 μg/ml) and then exposed to cisplatin at
various concentrations (0-10 μg/ml). Cells treated with
empty plasmid were used as the control. Cell viability
was determined at 24 h after treatment by using an
MTT assay. We demonstrated a strong synergistic anti-
tumor activity at the lower doses of the PMS2 plasmid
(2-4 μg/ml) and cisplatin (4-10 μg/ml) in HeLa cells by
CI (Figure 7B). The results therefore confirmed that
PMS2 transfection improved chemosensitization of cis-
platin on HeLa cells.
Discussion
The significance of MMR in the development of cervical
carcinoma has not been well documented, and few data
are available. It is known that the role of the DNA
MMR system is to maintain DNA replication fidelity by
repairing DNA mismatches and insertion/deletion loops
acquired during DNA replication [19]. This process is
highly conserved, from Escherichia coli to mammals.
PMS2 is a major component of the DNA mismatch
repair system. However, unlike other components,
PMS2 is highly unstable and germline PMS2 mutations
are rarely reported. PMS2 has recently emerged as an
attractive target due to its low rate of mutation and
unstabilization [20,21], raising the possibility that certain
types of exogenous DNA-damaging agents may rapidly
degrade PMS2 production and disrupt the MMR system
for facilitating carcinogenesis, and the rapid induction
and degradation of PMS2 may be essential for the bal-
ance between cell survival and death as a sensor of
environmental changes. In the present study, we found
a significant PMS2 downregulation in human cervical
carcinoma tissue, similar to the results found in other
cancers. Moreover, we provide the first evidence that
increased expression of phosphorylated GSK-3b (s9)
(GSK-3b inactivation) is negatively correlated with
PMS2 expression in cervical carcinoma and that GSK-
3b is able to stabilize PMS2 production in HeLa cells,
implicating a novel target to explore in the carcinogen-
esis and chemotherapy enhancement of human cervical
carcinoma.
Irrespective of gene mutations, varied levels of MMR
proteins have recently been reported in a variety of
tumors, such as colon cancer, lung cancer, and breast
cancer, that were responsible for the prognosis [22]. A
plausible explanation is that the disregulated DNA repli-
cation system is controlled and that no abnormal tran-
s c r i p t i o no fM M Rp r o t e i no c c u r si nn o r m a lc e l l s ,
whereas in the abnormal tumor cells, MMR genes are
rapidly activated and upregulated. Therefore, the loss of
MMR activity due to rapid degradation may lead to less
efficient gene repair, chemo-resistance and poor prog-
nosis. To investigate the importance of MMR protein in
this study, we firstly examined the expression of PMS2,
MSH2 and MLH1 in cervical carcinoma by
Figure 7 PMS2 enhances caspase-3 activity in HeLa cells and improves cisplatin chemosensitivity. Cells were transfected with the PMS2
plasmid and followed by a treatment with cisplatin for 0-36 h. (A), Caspase-3 activity was shown to be significantly increased after
administration of the PMS2 plasmid (2 μg/ml) in cisplatin-treated HeLa cells. (B), Effect of combined PMS2 and cisplatin on HeLa cells. The
combination index (CI) demonstrated a strong synergistic anti-tumor activity at lower doses of the PMS2 plasmid (2-4 μg/ml) and cisplatin (4-10
μg/ml) treatment in HeLa cells for 24 h.
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Page 10 of 13immunohistochemical staining. We found a significant
downregulation of PMS2 in cervical carcinoma compar-
ing to other protein. Furthermore, we detected PMS2
expression in cisplatin-induced HeLa cells and found a
significant upregulation of mRNA and protein, com-
pared to the control. The decrease of PMS2 activity in
tissue and the induction of PMS production in
HeLa cells suggested that the PMS2 protein may play a
more important role in the development of cervical
carcinoma.
Interestingly, we also found that PMS2 expression was
negatively correlated with GSK-3b inactivation in tumor
tissues, indicating that activated GSK-3b may stabilize
PMS2 production directly. It is now clear that GSK-3b
functions in diverse cellular processes including prolif-
eration, differentiation, survival, neoplastic transforma-
tion and tumor development [23]. The downstream
targets of GSK-3b include some well-recognized genes
such as Axin1, c-myc, b-catenin, snail, and MCL-1,
which have a close association with carcinogenesis.
Interestingly, all of them were found to share a similar-
ity in structure by possessing the common motif of S/T
XXX S/T. In our preliminary study, we found a consen-
sus motif of VSSSH GPSDP TDRAE in PMS2 by gene
sequencing. This finding indicated that PMS2 may be
recognized by GSK-3b, and additional studies will be
required to understand the interaction of GSK-3b and
PMS2 in cervical carcinoma. This finding, together with
the immunohistochemical results, raised the possibility
that GSK-3b may be able to stabilize PSM2 production
in cervical carcinoma. To prove our hypothesis, we
transfected the GSK-3b gene into HeLa cells and evalu-
ated the interaction of GSK-3b and PMS2 by using IP
with an antibody to GSK-3b and immunoblotting with
an antibody to PSM2. Surprisingly, we detected the
PSM2 production in the IP complex, which provided
the convincing evidence that GSK-3b is able to bind to
PMS2 protein.
GSK-3b has become an important area of investiga-
tion as a key component of the Wnt signaling pathway.
Unlike most protein kinases, GSK-3b is constitutively
active in resting cells, and it undergoes a rapid and tran-
sient inhibition in response to a number of external sig-
nals. To investigate the interaction of GSK-3b and
PMS2 in HeLa cells, we evaluated the effects of blocking
GSK-3b activity using a GSK-3b KD plasmid, GSK-3b
siRNA, and a specific inhibitor, LiCl, on the PMS2 pro-
duction in HeLa cells. Consistently, our results showed
that PMS2 production was downregulated in HeLa cells.
And we observed a concentration-dependent reduction
of PMS2 production in HeLa cells after administration
of GSK-3b siRNA and Lithium. Furthermore, we
observed co-location of GSK-3b and PMS2 protein in
HeLa cells by indirect immunofluorescence staining,
which was enhanced by transfection with GSK-3b WT
and GSK-3b CA, but not GSK-3b KD. Taken together,
these results provided evidence that GSK-3b is able to
stabilize PMS2 production in HeLa cells.
Furthermore, it is very important to note that cervical
cancer affects women at a higher incidence and a
younger age, with the increased prevalence of human
papillomavirus and alteration of socioeconimic condition
[24], and prolonged cisplatin treatment appears to
induce multiple mechanisms of tumor resistance [25].
On the other hand, the MMR system is also implicated
in the cellular response to DNA damage, and MMR
deficiency was thought to be responsible for drug resis-
tance during chemotherapy in a variety of cancers
[26-28]. PMS2 are able to activate cell cycle checkpoints
and apoptosis in response to persistent DNA damage
[29]. It is shown that PMS2 is required for cisplatin-
induced activation of p73, a member of the p53 family
of transcription factors with proapoptotic activity [30].
H o w e v e r ,t h es i g n i f i c a n c eo fP M S 2d e f i c i e n c yi nd r u g
resistance is controversial. Gibson et al. showed that
dysregulation of PMS2 gene expression can disrupt
MMR function in mammalian cells and establish an
additional carcinogenic mechanism by which cells can
develop genetic instability and acquire resistance to
cytotoxic cancer therapies [31]. In addition, Fedier et al.
investigated the effects of loss of PMS2 on the sensitivity
to a panel of widely used anticancer agents in E1A/Ha-
Ras-transformed p53-null mouse fibroblasts either profi-
cient or deficient in PMS2 and found that lack of the
PMS2 gene is associated with an increased sensitivity to
some types of anticancer agents such as cisplatin, oxali-
platin, and gemcitabine [32]. To investigate whether loss
of function of PMS2 plays a role in drug resistance in
HeLa cells or not, we examined the effects of PMS2
transfection on apoptosis of HeLa cells induced by cis-
platin using flow cytometry. We found that apoptotic
cells and caspase-3 activity increased significantly, com-
pared to the untreated cells. We also demonstrated a
strong synergistic anti-tumor activity at lower doses of
the PMS2 plasmid and cisplatin in HeLa cells by CI ana-
lysis. We therefore concluded that PMS2 upregulation
significantly enhanced cisplatin-associated chemosensi-
tivity, which may be useful for the treatment of cervical
carcinoma. On the other hand, we confessed that our
study contained some insufficiencies to investigate the
associated mechanisms underlying MMR-deficiency in
cervical carcinoma. The detailed mechanism underlying
MMR-deficiency in cervical carcinoma is still not fully
understood and other MMR components (MSH2,
MLH1, MSH6) may be functional related with PMS2,
which requires further study.
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Our results provide the preliminary evidence that GSK-
3b stabilized PMS2 production, which may play an
important role in the carcinogenesis and chemotherapy
of cervical carcinoma. This newly identified mechanism
will be helpful in better understanding tumor develop-
ment and in designing a novel therapeutic strategy for
the treatment of human cervical carcinoma.
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